A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).
Jerold Chun(Sanford Burnham Prebys Medical Discovery Institute), Volker Brinkmann(Unknown)
PubMed
September 1, 2011
Cited by 179
Related Papers
Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain
|Nature Biotechnology|2017|1.1k
Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain
|Science|2016|1.1k
LPA Receptors: Subtypes and Biological Actions
|The Annual Review of Pharmacology and Toxicology|2010|851
The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak
|Nature Medicine|2007|820
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
|Clinical Neuropharmacology|2010|794